CompletedNot Applicable

Effectiveness of Telephysical Therapy as a Secondary Stroke Prevention Tool in Patients With Minor Stroke.

Spain32 participantsStarted 2025-01-14

Plain-language summary

This study investigates the effectiveness of telephysiotherapy as a rehabilitation and secondary prevention tool in patients with minor stroke, TIA, or LACI, comparing an experimental group receiving tele-assisted aerobic and anaerobic exercises to a control group.

Who can participate

Age range

35 Years – 85 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis: Subjects with a diagnosis of minor stroke, TIA, or LACI immediately after hospital discharge. * Age: Between 35 and 85 years. * Technology access: Ownership of a smartphone with Android operating system and internet access. * Language skills: Ability to read, write, and understand instructions in Spanish, or the presence of a caregiver who can perform these tasks on behalf of the patient. * Motor impairment: Minimal motor sequelae, defined by: * "Timed Up and Go" (TUG) test: In less than 13.5 seconds. * Score of 3-5 points on the Functional Ambulatory Category (FAC). * Walking capacity: Ability to walk independently for 500 meters without technical or physical assistance. * Spasticity: Minimal or absent spasticity (score of 0-1 on Ashworth Scale Exclusion Criteria: * Oxygen dependency: Dependency on auxiliary oxygen. * Uncontrolled or unstable conditions: Including angina pectoris, hypertension (defined as resting systolic blood pressure \>180 mm Hg and diastolic \>110 mm Hg), arrhythmias (atrial/ventricular), sinus tachycardia (heart rate \>120/min), and diabetes mellitus. * Orthostatic hypotension: Drop in blood pressure \>20 mm Hg with associated symptoms. * Significant aortic stenosis: Defined as a diameter \<1 cm², or aortic dissection. * Uncompensated cardiac failure: Including third-degree atrioventricular block without a pacemaker, active myocarditis/pericarditis, and atrial fibrillation. * Recent embolism: Pulmonary or systemic emb…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Quality of life (SF-36)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Gait characteristics (GAITRite system and 6MWT)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Fall risk and functional mobility (TUG)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Balance (BBS)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Walking and assistance (FAC)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Fatigue associated with stroke (FSS)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Trial details

NCT IDNCT06780891

SponsorUniversity of Cadiz

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-31

View on ClinicalTrials.gov More Stroke trials

Who can participate

Age range

35 Years – 85 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Quality of life (SF-36)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Gait characteristics (GAITRite system and 6MWT)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Fall risk and functional mobility (TUG)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Balance (BBS)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Walking and assistance (FAC)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).

Fatigue associated with stroke (FSS)

Timeframe: Initial baseline assessment (week 1), assessment post-intervention (week 12) and assessment post-intervention 2 (week 24).